Need Help?

MP2PRT-MNG: Identifying Novel Molecular Markers of Response to Radiotherapy in Meningiomas Using Samples from the RTOG-0539 (NCT00895622)

The original NRG RTOG (Radiation Therapy Oncology Group)-0539 clinical trial was a nonrandomized phase II cooperative group trial in 2009. Patients with histologically confirmed diagnosis of meningioma were assigned to 1 of 3 risk groups based on 2007 WHO grade, resection extent, and recurrence status, and radiotherapy was given per protocol to the intermediate- and high-risk cases. As the translational component to this study, DNA methylation profiling, RNA-sequencing, and whole-exome sequencing were performed on clinical trial cases with available tissue for molecular analyte extraction and subsequent sequencing. Raw molecular data with metadata are available for this study.